Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Pharmacological Profile of Ibopamine

      Cardiology

      S. Karger AG

      Ibopamine, Dopamine receptors, Adrenergic receptors

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review summarizes the results obtained with ibopamine on anaesthesized dogs. Ibopamine is a dopamine-related drug active by oral route, namely the diisobutyric ester of N-methyl-dopamine. Ibopamine is able to activate dopamine specific and adrenergic receptors in the heart and circulation, inducing a vasodilating activity together with a mild positive inotropic effect without increasing heart rate and myocardial O<sub>2</sub> consumption. The activation of dopamine and adrenergic receptors mediates a direct vasodilation postjunctional DA<sub>1</sub> and β<sub>2</sub> receptors and an indirect vasodilation (presynaptic DA<sub>2</sub> and α<sub>2</sub>-receptors) through the inhibition of the release in norepinephrine, the renin-angiotensin system, and the secretion of aldosterone and vasopressin, thus antagonizing the neurohormonal alterations in congestive heart failure through a receptor mechanism. Ibopamine can also activate β<sub>1</sub> and β<sub>2</sub> and very modestly vascular synaptic α<sub>1</sub> – and α<sub>2</sub>-receptors thus inducing a mild positive inotropic activity and avoiding a drop in arterial pressure which might take place in presence of the intense vasodilation induced by the drug. There is some difference in potency between dopamine and epi-nine. Epinine is the active metabolite of ibopamine and is more active than dopamine on DA<sub>1</sub> DA<sub>2</sub>, α<sub>1</sub>, α<sub>2</sub> and β<sub>1</sub> and β<sub>2</sub> receptors. Ibopamine can be safely associated with captopril and digoxin but not with nifedipine.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5309-4
          978-3-318-01566-9
          0008-6312
          1421-9751
          1990
          1990
          12 November 2008
          : 77
          : Suppl 5
          : 22-29
          Affiliations
          Direzione Medica Area Italia, Simes, Zambon Group, Cormano-Milano, Italia
          Article
          174692 Cardiology 1990;77:22–29
          10.1159/000174692
          1980631
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Ibopamine in the Management of Congestive Heart Failure

          Comments

          Comment on this article